MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.

Autor: Chen, Jasmine1,2 (AUTHOR), Guanizo, Aleks C.1,2 (AUTHOR), Jakasekara, W. Samantha N.1,2 (AUTHOR), Inampudi, Chaitanya1,2 (AUTHOR), Luong, Quinton1,2 (AUTHOR), Garama, Daniel J.1,2 (AUTHOR), Alamgeer, Muhammad1,3,4 (AUTHOR), Thakur, Nishant1,2 (AUTHOR), DeVeer, Michael5 (AUTHOR), Ganju, Vinod1,2 (AUTHOR), Watkins, D. Neil6,7 (AUTHOR), Cain, Jason E.1,2 (AUTHOR), Gough, Daniel J.1,2 (AUTHOR) Daniel.gough@hudson.org.au
Zdroj: Journal of Experimental & Clinical Cancer Research (17569966). 4/26/2023, Vol. 42 Issue 1, p1-14. 14p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje